Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.88 |
| ▸ | HTT | P42858 | 3/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | RAB9A | P51151 | 2/20 | 0.88 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.63 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458104 | 1.00 | MEN1 (0.88) | MEN1HTTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL21458102 | 1.00 | MEN1 (0.88) | MEN1HTTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL12790000 | 0.94 | MEN1 (1.00) | MEN1HTTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL21458107 | 0.89 | MEN1 (0.70) | MEN1HTTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL16090511 | 0.80 | MEN1 (0.74) | MEN1HTTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL18962385 | 0.79 | MEN1 (0.72) | MEN1HTTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL1604211 | 0.78 | MEN1 (0.71) | MEN1HTTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL12710494 | 0.78 | MEN1 (0.71) | MEN1HTTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL1604026 | 0.77 | LMNA (1.00) | MEN1HTTSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL19317179 | 0.77 | MEN1 (0.67) | MEN1HTTSMN1; SMN2KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118203670-A | Lipid nano regulator for sensitized iron death and preparation method and application thereof | 沈阳药科大学 | 2024-06-18 | — | — | CN | claimed |
| CN-117757744-A | Culture medium for enhancing T cell function and dryness and application thereof | 中山大学 | 2024-03-26 | — | — | CN | claimed |
| US-11679111-B2 | Fatty acid synthase inhibitors | DUKE UNIVERSITY (US) | 2023-06-20 | — | — | US | claimed |
| US-20210338676-A1 | FATTY ACID SYNTHASE INHIBITORS | DUKE UNIVERSITY (US) | 2021-11-04 | — | — | US | claimed |
| US-10966981-B2 | Fatty acid synthase inhibitors | DUKE UNIVERSITY (US) | 2021-04-06 | — | — | US | claimed |
| US-20190314376-A1 | FATTY ACID SYNTHASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-17 | — | — | US | claimed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109746-A1 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4719608-A1 | QUINAZOLINYL-INDAZOLE DERIVATIVES AS THERAPEUTIC COMPOUNDS FOR HIV | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720056-A1 | SOLID FORMS OF COMPOUNDS USEFUL IN THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4698174-A1 | DOSING REGIMEN OF CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-3980070-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | Genfit (FR) | 2022-04-13 | — | — | EP | disclosed |
| EP-3972645-A1 | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022046644-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20210338676-A1 | FATTY ACID SYNTHASE INHIBITORS | DUKE UNIVERSITY (US) | 2021-11-04 | — | — | US | disclosed |
| US-10966981-B2 | Fatty acid synthase inhibitors | DUKE UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190314376-A1 | FATTY ACID SYNTHASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109746-A1 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | IL15, IL15RA, CD4 | MEN1 973/4885HTT 4179/4885SMN1; SMN2 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.